Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High - Here's Why

Key Points

• Vaxcyte shares surged to a new 52-week high of $89 after the company reported that its VAX-31 pneumococcal vaccine met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 adult trial.
• VAX-31 showed broad serotype coverage and strong immune responses versus existing vaccines, improving prospects for regulatory filings and commercialization, though investors still await detailed safety and immunogenicity data.
• Analysts remain broadly positive, with six Buy ratings, one Hold and one Sell; the stock has a “Moderate Buy” consensus and an average price target of $106.20, compared with a market capitalization of about $12.33 billion.

Shares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) reached a new 52-week high on Monday. The company traded as high as $89.00 and last traded at $87.1950, with a volume of 1927060 shares trading hands. The stock had previously closed at $56.48.

Vaxcyte News Summary

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: VAX-31 met all prespecified primary endpoints across the adult age groups studied, compared with Prevnar 20 (PCV20) and/or Capvaxive (PCV21). The result removes a major clinical-development hurdle for Vaxcyte’s lead vaccine candidate. Vaxcyte Reports Positive Topline Data from OPUS-1
• Positive Sentiment: The vaccine demonstrated broad serotype coverage and strong immune responses, supporting Vaxcyte’s positioning of VAX-31 as a potentially differentiated competitor in the adult pneumococcal vaccine market. Broader Coverage and Strong Immune Responses Highlight Vaxcyte’s Phase 3 Vaccine Readout
• Positive Sentiment: Multiple reports characterized the primary-endpoint results as successful, triggering a significant investor response and improving the outlook for regulatory submissions and eventual commercialization. Vaxcyte Says Pneumococcal Vaccine Phase 3 Trial Meets Primary Endpoints
• Neutral Sentiment: The company scheduled a webcast and conference call to review the OPUS-1 topline data, with additional details on safety, tolerability and immunogenicity likely to be important for assessing the results. Vaxcyte to Host Webcast and Conference Call to Present OPUS-1 Data
• Neutral Sentiment: The announcement contains topline results rather than a complete clinical dataset. Investors will still monitor detailed safety findings, regulatory discussions, filing timelines and the competitive response from marketed pneumococcal vaccines.

Analyst Ratings Changes

PCVX has been the subject of several recent analyst reports. Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Needham & Company LLC reissued a "buy" rating and set a $110.00 price objective on shares of Vaxcyte in a research report on Friday, September 25th. Bank of America reduced their price objective on shares of Vaxcyte from $133.00 to $130.00 and set a "buy" rating for the company in a research note on Monday, September 28th. Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Finally, Guggenheim upped their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a "buy" rating in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $106.20.

Vaxcyte Price Performance

The company has a market capitalization of $12.33 billion, a PE ratio of -10.85 and a beta of 1.23. The firm has a 50-day moving average of $58.67 and a 200 day moving average of $56.18.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the business earned ($1.22) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Insider Transactions at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the transaction, the insider owned 76,756 shares in the company, valued at $4,221,580. This represents a 18.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 3,477 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39. Following the completion of the transaction, the chief operating officer directly owned 155,041 shares in the company, valued at approximately $9,468,353.87. The trade was a 2.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 55,890 shares of company stock worth $3,111,189 in the last ninety days. Insiders own 3.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc grew its position in shares of Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company's stock valued at $33,000 after acquiring an additional 236 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Vaxcyte by 1,924.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 830 shares of the company's stock worth $38,000 after buying an additional 789 shares in the last quarter. Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte in the first quarter worth about $58,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Vaxcyte during the 4th quarter valued at about $63,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Vaxcyte by 68.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,248 shares of the company's stock valued at $73,000 after acquiring an additional 507 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte's lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.